Original Research
Accepted on 18 Nov 2025
Blinatumomab combined with low-dose chemotherapy and Tyrosine Kinase Inhibitors as first-line induction for newly diagnosed Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: Improved efficacy and reduced toxicity
in Hematology